Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | GAA | P10253 | 5/20 | 0.61 |
| ▸ | GLA | P06280 | 4/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | GALR3 | O60755 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9701575 | 0.96 | MDM2 (0.59) | MDM2KDM4EALDH1A1GAAGLA | |
| SCHEMBL3673913 | 0.83 | ATM (0.53) | MDM2KDM4EALDH1A1GAAGLA | |
| SCHEMBL11738299 | 0.82 | MDM2 (0.47) | MDM2KDM4EALDH1A1GAAGLA | |
| SCHEMBL9701560 | 0.82 | KDM4E (0.59) | MDM2KDM4EALDH1A1GAAGLA | |
| SCHEMBL11737297 | 0.82 | ERCC1 (0.57) | MDM2KDM4EALDH1A1GAAGLA | |
| SCHEMBL10985180 | 0.82 | KDM4E (0.55) | MDM2KDM4EALDH1A1GAAGLA | |
| SCHEMBL11008749 | 0.82 | MCL1 (0.51) | MDM2KDM4EALDH1A1GAAGLA | |
| SCHEMBL7365683 | 0.82 | KDM4E (0.51) | MDM2KDM4EALDH1A1GAAGLA | |
| SCHEMBL9700724 | 0.82 | KDM4E (0.66) | MDM2KDM4EALDH1A1GAAGLA | |
| SCHEMBL4471712 | 0.80 | ALDH1A1 (0.53) | MDM2KDM4EALDH1A1GAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1646125-A | Substituted pyridones as modulators of P38MAP kinase | PHARMACIA CORP (US) | 2005-07-27 | — | — | CN | claimed |
| EP-1490064-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | Pharmacia Corporation (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | claimed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| EP-3994125-B1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| EP-3994125-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2021003295-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021003295-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| CN-101531631-B | Substituted pyridinones as modulators of p38 map kinase | PHARMACIA CORP | 2011-09-28 | — | — | CN | disclosed |
| EP-0826671-B1 | HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USE OF THE SAME | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
| US-5948785-A | USEFUL AS CHYMASE INHIBITORS AND CAN BE EFFECTIVE FOR THE PROPHYLAXIS AND TREATMENT OF VARIOUS DISEASES CAUSED BY CHYMASE, SUCH AS THOSE CAUSED BY ANGIOTENSIN II. | THE GREEN CROSS CORPORATION (JP) | 1999-09-07 | — | — | US | disclosed |
| WO-1998045266-A1 | 3-AMINOPYRIDINE DERIVATIVES FOR TREATMENT OF INFLAMMATORY AND MALIGNANT DISEASES | FERRING B.V. (NL) | 1998-10-15 | — | — | WO | disclosed |
| EP-0826671-A1 | HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USE OF THE SAME | THE GREEN CROSS CORPORATION (JP) | 1998-03-04 | — | — | EP | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | MDM2 2729/4885KDM4E 3109/4885ALDH1A1 465/4885 |
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | MDM2 3917/4885KDM4E 3869/4885ALDH1A1 787/4885 |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | MDM2 2729/4885KDM4E 3109/4885ALDH1A1 465/4885 |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | HSD17B3, HSD17B11, HSD17B1 | MDM2 2729/4885KDM4E 3109/4885ALDH1A1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.